Rheumatoid arthritis (RA) is associated with excess cardiovascular morbidity and mortality, predominantly due to coronary artery and cerebrovascular disease which seem to be secondary to accelerated atherosclerosis (1-5). Vascular involvement in RA shows some peculiar features including a weaker correlation with traditional cardiac risk factors and a strong correlation with early inflammatory poliarthritis and presence of rheumatoid factor (1-5). Notably the vascular damage in RA is usually not related to specific rheumatoid vasculitis or cardiomyopathy nor to secondary amyloidosis (6) (7) .
In connective tissue diseases overt cardiovascular involvement manifests itself with a high occurrence of symptomatic myocardial ischemia or infarction, and is preceded by a long subclinical period characterized by early endothelial dysfunction and subsequent endothelial damage, which represent basic mechanisms ofatherosclerosis (3, 6, (8) (9) (10) .
Mechanisms of endothelial dysfunction in RA include the interaction of the endothelium with acute-phase proteins, rheumatoid factor and various proinflammatory cytokines, such as tumor necrosis factor-a (TNFa) and interleukin-l, leading to vascular damage and accelerated atherosclerosis (2, (6) (7) (10) (11) .
Atherosclerosis is now regarded as an inflammatory disease, in which TNFa plays a pivotal role also by inducing endothelial dysfunction, which can be detected by a poor or abnormal vasomotor response to pharmacological agents such as acetylcholine, bradykinin, serotonin, substance P or physical stimuli such as shear stress (12) (13) . Functional endothelial abnormalities are thought to precede the development of the anatomical changes of atherosclerosis (13) (14) .
Currently, it has been demonstrated that anti-TNF-a treatment provides clinical benefits by reducing RA activity and improving the disease process (15) (16) (17) (18) ; thus, it is plausible that TNFa antagonism might counteract the unfavourable effect of this cytokine also at the vascular level when taking into account the role of TNFa on endothelial dysfunction such as previously reported in chronic heart failure (19) (20) . Endothelial damage is considered a shared pathway for a broad spectrum of noxious agents ranging from classic risk factors to those newly recognized such as the inflammatory cytokines (11-12), and is preceded by endothelial dysfunction which is accepted as a surrogate marker of coronary artery atherosclerosis in clinical studies (3, 6) .
Endothelial dysfunction encompasses changes of any of the antiinflammatory, anticoagulant, and adhesive properties of the endothelial cells with over-expression of adhesion molecules and inflammatory cell recruitment, and also an impairment of the vasodilatory responses which is easily and reliably studied (13) (14) . Such abnormal arterial tone regulation, due to many impaired molecular mechanisms, possibly modulated by TNFa, might result in the reduced endothelialdependent vasodilation which is sometimes associated to abnormal vasocostrictive reactions (13) (14) .
The ai m of the present study was to assess the occurrence of endothelial dysfunction in patients with RA and the effects of anti-TNF-a treatments on endothelial function of RA patients.
MATERIALS AND METHODS
We evaluated 10 women, aged 54.3 ± 8.7 years (range 36 -65 yrs), with RA for at least 4 months (mean 105±96 month, range 5-331 months), diagnosed according to ACR criteria. Disease Activity Score (DAS) was~3.7 despite treatment with at least two disease-modifying antirheumatic drugs (DMARDS) for~4 months. All patients received corticosteroids, five patients were treated with methotrexate, seven patients were affected with mild hypertension and two were hypercholesterolemic, treated with statins. One patient was a current smoker. All patients were participants of the observational study "Antares" of the Italian Ministry of Health.
Evaluation of patients included complete history, physical examination, routine laboratory tests, and determination of C-reactive protein, erythrocyte sedimentation rate, rheumatoid factor, antinuclear antibodies, and anti-dsDNA antibodies; the patients also underwent tine test, chest X-ray and Doppler echocardiogram at the time of the study.
Patients were excluded in the presence of conditions which contraindicated anti-TNFo: treatment such as pregnancy, infections, malignancy, heart, renal or li ver failure.
The effects of the treatment on RA were assessed by clinical and laboratory evaluation, the Disease Activity Score (DAS) and the Health Assessment Qual ity (HAQ) scores. Anti-TNF 0: treatment was added to the previous treatment, which remained unchanged throughout the entire course of the study.
Five patients, all of them taking methotrexate, were treated with infliximab (Remicade: Schering-Plough, Milano, Italy; Centocor B.Y., Leiden, the Netherlands), administered intravenously at the dosage of3 mg/kg over 2 hours. The treatment with infliximab was repeated after 2 weeks, after another 4 weeks and subsequently every 8 weeks. The other five patients were treated with etanercept (Enbre!: Wyeth Lederle, Aprilia, Italy; Wyeth Europe, Berkshire, United Kingdom), 25 mg administered subcutaneously twice a week. All patients gave written informed consent. The control group consisted of 15 women, aged 53 ±9 yrs (p =: ns).
Endothelial function study
Endothelial function was studied using ultrasound technique according to current guidelines (21) (22) . Brachial artery reactivity was assessed in the morning after an overnight fast; patients maintained in adecumbent position for 20 minutes, at a room temperature of 22°C. The imaging of the brachial artery, 2-5 em above the antecubital fossa, was obtained by high resolution ultrasonographic device equipped with a 10 MHz lineararray transducer (Agilent ImagePoint Hx, Agilent Technologies, MA, USA). The left brachial artery was scanned over a longitudinal section, obtaining good quality frames synchronized on the R wave of the ECG. The brachial artery blood flow velocity was measured by means of pulsed-wave Doppler signal, placing the sample volume in the center of the artery; peak flow rate echo-Doppler measurements were performed on the brachial artery at rest, during reactive hyperemia and after sublingual nitrate administration. Measurements of the artery internal diameter were taken from the anterior to the posterior wall at the interface between media and intima or to the hardest echo ("M" line), at end diastole (22) ; the ultrasound transducer was maintained on the brachial artery by a dedicated stereotactic probe-holding device.
The endothelium-dependent flow-mediated vasodilation (FMD) was assessed by measuring the maximal increase in the internal diameter of the brachial artery during reactive hyperemia evoked by the release of a cuff inflated to 250 mrn Hg for five minutes on the upper arm, distal to the measurement site. After cuff deflation, the maximal peak tlow rate was measured at 15" and 30"; the changes in brachial artery diameter were measured each 30" for six minutes and were reported as a percentage of the baseline. Reference normal values for FMD were~6% (22) .
After a rest period of 15 minutes, baseline measurements (diameter and flow velocity) of the brachial artery were repeated, and the endothelium-independent vasodilation was evaluated by sublingual administration of 300 meg of nitroglycerin spray; subsequently, the diameter of the brachial artery was measured at 30 second intervals for 7 minutes, and changes in brachial artery diameter were reported as percent of basal values.
Endothelial function was evaluated at baseline, after I day and after 1,2 and 6 weeks from the beginning of the anti-TNF-ex treatment.
Statistical analysis
Data are expressed as mean ::':::SD if not otherwise stated. Obtained variables were tested for normal distribution by the Anderson-Darling test. The values obtained in each group and the differences between measurements were analyzed by paired or unpaired Student's t-test or by analysis of variance (ANOVA) for repeated measurements, followed by Bonferroni's test; the Wilcoxon test was used when otherwise appropriate. Linear regression analysis with Pearson correlation coefficient was used to investigate the relationship between variables. Results were considered statistically significant if p < 0.05.
RESULTS
Patients with RA showed a baseline flowmediated vasodilation significantly lower than normalsubjects(3.8±3.7%vs 13.7±5.1, p<O.05) which resulted under the minimal normal value in 7 cases, thus demonstrating the presence of endothelial dysfunction in our RA patient population Tab. I. Clinical and laboratory parameters during anti-TNFex treatment.
Baseline
After treatment (mean -SD) (mean -SD) P There was no significant difference between the two anti-TNF<x treatments regarding mean percentage increase of flow-mediated vasodilation during treatment. The vascular response to the two anti-TNF<x treatments showed slightly different patterns, with infliximab causing a progressive improvement of brachial artery flow-mediated vasodilation and etanercept causing a less stable improvement (Fig. 1) .
RA clinical improvement was demonstrated by a significant decrease in the DAS score (from 6.26± 1.6 to 5.26± 1.38, p=::::; 0.05) (Tab. I).
In one case we observed an early transitory improvement in both rheumatoid disease activity and endothelial dysfunction after anti-TNF<x treatment, followed by a decline in the effect of anti-TNF<x treatment in restoring arterial vasoreactivity, which preceded a later reduction in the clinical response of joint disease activity.
Amongst the clinical and laboratory parameters evaluated during the study, the values of the erythrocyte sedimentation rate were significantly lowered from52.5±40.8 to 21.9± 15.5 mmJh (p =: : : : ; 0.05) and C-reactive protein values decreased from 3.15 ±4.3 to 0.6±0.9 mg/L (p=::::; 0.05), without significant changes in rheumatoid factor (from 235 .8 235.5 to 227.8 224 U/l , p =ns); triglyceride (from 105.5±47.1 to 112.3±56.2 mg %, p = ns) and cholesterol serum levels (from 195.6±49.8 to 214.1± 66 mg%, p = ns) did not show any statistically significant change (Tab. I) .
Systolic and diastolic blood pressure showed no significant changes during the course of the study (Tab. I).
An inverse relationship between endotheliumdependent vasodilation and erytrocyte sedimentation rate values was observed (r -0.48; p=::::; 0.05).
DISCUSSION
The present study provides evidence of the high occurrence of endothelial dysfunction in RA, demonstrates that endothelial dysfunction is clearly reversed by both TNF<x antagonist treatments we employed, and thus confirms the hypothesis of the pivotal role of TNF<x as a mediator of systemic and vascular wall inflammation in RA (1-2,6-7,11).
In our patient population a high incidence of endothelial dysfunction was found, suggesting that abnormal vasoreactivity may be a prominent feature of RA, supporting other studies (9) (10) 23) . However, the study protocol regarding anti-TNF<x treatment only to patients affected with uncontrolled inflammatory joint disease resistant to at least two DMARDS may have introduced an unavoidable selection bias. In addition, all patients had a long immunosuppressive treatment history, including methotrexate and corticosteroids, due to the long duration of their disease (2, (4) (5) (6) .
After both anti-TN Fa treatments we observed an impressive and persistent improvement in flowmediated brachial artery vasodilation associated with clinical and laboratory improvement, characterized by a significant decrease of DAS score and active phase reactants. Our findings demonstrate the major role of TNFa in causing endothelial dysfunction when taking into account the favourable changes obtained with two different modalities of TNFa specific antagonism, irrespective of the remaining pharmacologic schemes and the small and insignificant changes occurring in cholesterol, triglyceride and blood pressure levels (23) . The reversibil ity of endothelial dysfunction is shared by both drug regimens, although with subtle differences, likely due to their biological and pharmacological properties, resulting in a prompt but declining effect possibly due to a shorter half-life for etanercept, while infliximab is capable of a more prolonged and sustained TNFa neutralizing activity (24) .
The pivotal role played by TN Fa in RA endothelial dysfunction is convincingly supported by our data showing the clear effects of both etanercept and infliximab, when administered alone or in combination with usual DMARDS and corticosteroids, that per se reportedly could play controversial effects on RA vascular changes (4) (5) (6) .
Clinical and experimental studies lend support to the notion that anti-TNFa treatments may selectively counteract endothelial dysfunction, related to a systemic inflammation (25) , through several mechanisms resulting both in increased endothelial nitric oxide synthase biodisponibility and in blocked vascular overexpressed inducible nitric oxide synthase (9, I 9-20,23,26-28). Our findings showed an early and persistent reversibility of cytokine-induced endothelial dysfunction contemporarily with a significant erythrocyte sedimentation rate and C-reactive protein reduction concurrently with DAS improvement, thus suggesting that endothelial dysfunction is a relevant feature of the rheumatoid disease process and is driven by TNFa (6, 9, 11, 29) .
At the present time, in other clinical conditions such as advanced renal impairment ordyslipidaemia, endothelial dysfunction is considered a non-invasive marker of subsequent and overt cardiovascular involvement (3,6, II, I 4), and similarly it could be regarded as a biomarker of cardiovascular involvement in RA, induced by the same mechanisms of rheumatoid inflammation (6, 9, 30) , pharmacologically modifiable and probably preceding asymptomatic or overt cardiovascular morbidity (2, (13) (14) . Further studies are required in order to establish the long term significance of endothelial dysfunction and its clinical relevance for assessing cardiovascular involvement in RA patients and their complete and successful treatment (3, 6, 9, 23) .
